Devinsky O, Vezzani A, O’Brien TJ, Jette N, Scheffer IE, de Curtis M, Epilepsy PP (2018) Nat Rev Dis Primers 4:18024

PubMed  Google Scholar 

Melzer N, Rosenow F (2024) Autoimmune-associated epilepsy—a challenging concept. Seizure https://doi.org/10.1016/j.seizure.2024.05.017

Rada A, Bien CG (2023) What is autoimmune encephalitis-associated epilepsy? Proposal of a practical definition. Epilepsia 64:2249–2255

CAS  PubMed  Google Scholar 

Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, McKeon A, Shao XQ, Venegas V, Bien CG (2020) Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia 61:1341–1351

PubMed  Google Scholar 

Gemeinsamer Bundesausschuss https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/off-label-use/

Scheffer IE, Zuberi S, Mefford HC, Guerrini R, McTague A (2024) Developmental and epileptic encephalopathies. Nat Rev Dis Primers 10:61

PubMed  Google Scholar 

Willems LM, Hamer HM, Knake S, Rosenow F, Reese JP, Strzelczyk A (2019) General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data. Appl Health Econ Health Policy 17:707–722

PubMed  Google Scholar 

Willems LM, Hochbaum M, Zöllner JP, Schulz J, Menzler K, Langenbruch L, Kovac S, Knake S, von Podewils F, Hamacher M, Hamer HM, Reese JP, Frey K, Rosenow F, Strzelczyk A (2022) Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Epilepsia 63:1591–1602

PubMed  Google Scholar 

Bast T (2018) Medikamentöse Therapie fokaler Anfälle bei Kindern. Z Epileptol 32:126–134

Google Scholar 

Bast T (2024) Zulassungsstatus der wichtigsten anfallssuppressiven Medikamente. In: Bast T, Krämer G. Medikamenten-Pocket Epilepsie, S 97–102. Springer Berlin Heidelberg 2024

Maltseva M, Rosenow F, von Podewils F, Habermehl L, Langenbruch L, Bierhansl L, Knake S, Schulz J, Gaida B, Kämppi L, Mann C, Strzelczyk A (2024) Predictors for and use of rescue medication in adults with epilepsy: A multicentre cross-sectional study from Germany. Seizure 118:58–64

PubMed  Google Scholar 

Zemberi JM, Gidal BE, Kotloski RJ (2023) Seizure clusters: diagnostic and therapeutic advances. Clin Epileptol 36:266–272

Google Scholar 

Klotz KA, Bast T, Strzelczyk A, Schubert-Bast S (2023) Akuter epileptischer Anfall – Handlungspläne für Laien (HEAL) und Therapeuten (HEAT). Clin Epileptol 36:273–279

Google Scholar 

Guideline NICE (2022) Epilepsies in children, young people and adults; https://www.nice.org.uk/guidance/ng217

Google Scholar 

Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O, Marigold Trial G (2022) Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol 21:417–427

CAS  PubMed  Google Scholar 

Holtkamp M, May TW, Berkenfeld R, Bien CG, Coban I, Knake S, Michaelis R, Rémi J, Seeck M, Surges R, Weber Y, Baum P, Baumgartner C, Beyenburg S, Brandt C, Brodisch P, Brückner S, Chatzikonstantinou A, Conrad S, Fauser S, Focke N, Freiman T, Freitag H, Fudali M, Geiger-Riess M, Greshake B, Grimmer A, Hebel J, Held L, Kaufmann E, Kerling F, Knieß T, Kollmar R, Krämer G, Kürsten K, Laufs H, Lüsebrink A, Lutz M, Möddel G, Müffelmann B, Noachtar S, Rösche J, Rozinat K, Rüegg S, Schäfer U, Schmidt PM, Schmitt FC, Schmitt J, Schneider UC, Schulze-Bonhage A, Speicher P, Strzelczyk A, Stutterheim K, Thorbecke R, Trollmann R, Urbach H, von Oertzen TJ, von Podewils F, von Wrede R, Wagner K, Weber R, Wehner T, Wendtland F, Winter Y, Woermann F, Zieglgänsberger D (2024) Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Clin Epileptol 37:118–139

Google Scholar 

Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C, Whitesides J, Fakhoury T (2018) Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies. Epilepsy Res 141:73–82

CAS  PubMed  Google Scholar 

Lattanzi S, Foschi N, Martellino C, Audenino D, Boero G, Bonanni P, Ferlazzo E, Chiesa V, Dainese F, Piccioli M, Ferrari A, Labate A (2024) Conversion to Brivaracetam Monotherapy in Clinical Practice: A Retrospective Study. Neurol Ther 13:389–398

PubMed  PubMed Central  Google Scholar 

Kühne F, Becker LL, Bast T, Bertsche A, Borggraefe I, Bosselmann CM, Fahrbach J, Hertzberg C, Herz NA, Hirsch M, Holtkamp M, Janello C, Kluger GJ, Kurlemann G, Lerche H, Makridis KL, von Podewils F, Pringsheim M, Schubert-Bast S, Schulz J, Schulze-Bonhage A, Steinbart D, Steinhoff BJ, Strzelczyk A, Syrbe S, De Vries H, Wagner C, Wagner J, Wilken B, Prager C, Klotz KA, Kaindl AM (2023) Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open 8:360–370

PubMed  PubMed Central  Google Scholar 

Coppola G, Zamponi N, Kluger G, Mueller A, Rita AM, Parisi P, Isone C, Santoro E, Curatolo P, Verrotti A (2013) Rufinamide for refractory focal seizures: an open-label, multicenter European study. Seizure 22:33–36

PubMed  Google Scholar 

Habermehl L, Mross PM, Krause K, Immisch I, Chiru D, Zahnert F, Gorny I, Strzelczyk A, Rosenow F, Möller L, Menzler K, Knake S (2021) Stiripentol in the treatment of adults with focal epilepsy—a retrospective analysis. Seizure 88:7–11

CAS  PubMed  Google Scholar 

Bjørk M‑H, Vegrim H, Alvestad S, Bjørke-Monsen A‑L, Riedel BMI, Gilhus NE, Husebye ESN (2023) Pregnancy, folic acid, and antiseizure medication. Clin Epileptol 36:203–211

Google Scholar 

Schiller K, Schiller V, Rauchenzauner M (2023) Gender-specific aspects in pediatric epileptology. Clin Epileptol 36:212–216

Google Scholar 

Stephen LJ, Brodie MJ (2020) Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults. CNS Drugs 34:147–161

PubMed  Google Scholar 

Daquin G, Bonini F (2024) The landscape of drug resistant absence seizures in adolescents and adults: Pathophysiology, electroclinical spectrum and treatment options. Rev Neurol (paris) 180:256–270

CAS  PubMed  Google Scholar 

Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S, Kowski A, Kunz R, Kurlemann G, Langenbruch L, Möddel G, Müller-Schluter K, Reif PS, Schubert-Bast S, Steinhoff BJ, Steinig I, Willems LM, von Podewils F, Rosenow F (2018) Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 59:1549–1556

CAS  PubMed  Google Scholar 

Lince-Rivera I, Cordoba NM, la Rosa JSO (2022) Narrative review of brivaracetam for genetic generalized epilepsies. Seizure 103:72–81

PubMed  Google Scholar 

Marinas A, Villanueva V, Giraldez BG, Molins A, Salas-Puig J, Serratosa JM (2009) Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 11:61–66

PubMed  Google Scholar 

Velizarova R, Crespel A, Genton P, Serafini A, Gelisse P (2014) Zonisamide for refractory juvenile absence epilepsy. Epilepsy Res 108:1263–1266

CAS  PubMed  Google Scholar 

Wirrell EC, Lagae L, Scheffer IE, Cross JH, Specchio N, Strzelczyk A (2024) Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. Epilepsia Open 9:1643-1657

Strzelczyk A, Schubert-Bast S (2021) Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs 35:61–83

PubMed  PubMed Central  Google Scholar 

Strzelczyk A, Schubert-Bast S (2022) A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs 36:217–237

PubMed  PubMed Central  Google Scholar 

Muhle H, Kurlemann G, Lehmann I, Hamer H, Mayer T, Potschka H, Schubert-Bast S, Strzelczyk A, Pringsheim M (2024) Fenfluramine in clinical practice: new therapy option for Dravet and Lennox-Gastaut syndromes. Clin Epileptol 37:68–78

Google Scholar 

Schulze-Bonhage A (2019) „Orphan drugs“ in der Epileptologie. Z Epileptol 32:277–285

Google Scholar 

Pietrafusa N, Trivisano M, Casellato S, Correale C, Cappelletti S, De Liso P, Onida I, Sotgiu S, Butera A, Specchio N, Vigevano F (2024) Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy? Epilepsia 65:e7–e13

CAS  PubMed  Google Scholar 

Willems LM, Bertsche A, Bösebeck F, Hornemann F, Immisch I, Klein KM, Knake S, Kunz R, Kurlemann G, Langenbruch L, Möddel G, Müller-Schluter K, von Podewils F, Reif PS, Steinhoff BJ, Steinig I, Rosenow F, Schubert-Bast S, Strzelczyk A (2018) Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany. Front Neurol 9:569

PubMed  PubMed Central  Google Scholar 

Falcicchio G, Lattanzi S, Negri F, de Tommaso M, La Neve A, Specchio N (2022) Treatment with Cenobamate in Adult Patients with Lennox-Gastaut Syndrome: A Case Series. J Clin Med 12:129

Grosso S, Coppola G, Cusmai R, Parisi P, Spalice A, Foligno S, Verrotti A, Balestri P (2014) Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. Acta Neurol Scand 129:420–424

CAS  PubMed  Google Scholar 

Matricardi S, Cesaroni E, Bonanni P, Foschi N, D A A, DiGennaro G, Striano P, Cappanera S, Siliquini S, Freri E, Ragona F, Granata T, Deleo F, Villani F, Russo A, Messana T, Siri L, Bagnasco I, Vignoli A, Operto FF, Orsini A, Bonuccelli A, Papa A, Peruzzi C, Liguori C, Verrotti A, Chiarelli F, Marini C, Lattanzi S (2023) Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. Epilepsia 64: e98:e104

Google Scholar 

Ohtahara S (2006) Zonisamide in the management of epilepsy—Japanese experience. Epilepsy Res 68(Suppl 2):S25–33

CAS  PubMed  Google Scholar 

Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D (2018) Open-label use of highly purified CBD (Epidiolex(R)) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav 86:131–137

PubMed  Google Scholar 

Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F (2021) Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs 35:265–281

PubMed  PubMed Central  Google Scholar 

Patel S, Geenen KR, Dowless D, Bruno PL, Thiele EA (2023) Follow-up to low-dose fenfluramine for Sunflower syndrome: A non-randomized controlled trial. Dev Med Child Neurol 65:961–967

PubMed